21.22 0.00 (0.00%)
After hours: 4:54PM EDT
|Bid||21.22 x 800|
|Ask||21.23 x 1400|
|Day's Range||21.14 - 21.71|
|52 Week Range||17.53 - 33.00|
|Beta (3Y Monthly)||0.72|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.43|
Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector. Here ...
A lawyer for former pharmaceutical executive Martin Shkreli on Friday urged a federal appeals court to overturn Shkreli's criminal conviction for defrauding investors in hedge funds he founded. The lawyer, Mark Baker, argued that the jury that convicted Shkreli was given incorrect instructions about securities fraud. Baker faced a barrage of skeptical questions from a three-judge panel during a brief proceeding in the 2nd U.S. Circuit Court of Appeals in Manhattan.
How far off is Retrophin, Inc. (NASDAQ:RTRX) from its intrinsic value? Using the most recent financial data, we'll...
In this article we are going to estimate the intrinsic value of Retrophin, Inc. (NASDAQ:RTRX) by taking the expected...
A Retrophin spokeswoman confirmed Thursday that the settlement covers Shkreli’s $30 million lawsuit from last month.
Martin Shkreli, the pharmaceutical entrepreneur serving a seven-year prison term for fraud, has settled all outstanding disputes with Retrophin Inc, the biopharmaceutical company he founded in 2011 and which ousted him three years later. A Retrophin spokeswoman said on Thursday that the accord covers Shkreli's $30 million lawsuit last month accusing three former colleagues, including his successor as chief executive, of engineering his ouster and to enrich themselves from his work. The settlement also covers claims Retrophin first raised in August 2015, in a $65 million lawsuit accusing Shkreli of repeatedly breaching his duty of loyalty to the San Diego-based company.
Retrophin, Inc. (RTRX) today announced that it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and patient advocacy foundation Alagille Syndrome Alliance (ALGSA) to collaborate on research efforts aimed at the identification and development of potentially novel therapeutics for Alagille syndrome (ALGS). ALGS is a rare and debilitating disease characterized by severe liver and cardiovascular abnormalities.
While small-cap stocks, such as Retrophin, Inc. (NASDAQ:RTRX) with its market cap of US$768m, are popular for their...
Martin Shkreli, the pharmaceutical entrepreneur serving a seven-year prison term for fraud, on Friday sued three former colleagues at Retrophin Inc for more than $30 million, saying they illegally ousted him from that company in 2014. In a complaint filed in Manhattan federal court, Shkreli said Stephen Aselage, Margaret Valeur-Jensen and Gary Lyons fraudulently induced him to negotiate his exit from Retrophin, only to then "trick him" into signing away his rights as chief executive and founder without receiving anything in return. Shkreli said the defendants were "driven by their egos, jealousy, and greed," and that Aselage and Valeur-Jensen then "paid themselves" more than $35 million from assets he created.
Notorious 'pharma bro' Martin Shkreli is sued two directors and the ex-general counsel of his former biopharmaceutical company Retrophin for more than $30 million, accusing them of using fraud to oust him as head of the firm in 2014. It was lodged within days of him being transferred to a new prison in Pennsylvania, where he will continue serving a seven-year sentence for securities fraud related to Retrophin and two hedge funds, which financially collapsed under his operation. Shkreli gained national infamy in 2015 after his Turing Pharmaceuticals, now known as Phoenixus AG, hiked the price of its drug Daraprim by more than 5,000%.
SAN DIEGO, May 30, 2019 -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in June:.
Retrophin, Inc. (RTRX) today announced the appointment of Sandra E. Poole to the Company's Board of Directors, effective immediately. Ms. Poole brings more than 25 years of biopharmaceutical industry experience in manufacturing strategy, including chemistry, manufacturing and controls (CMC), technical operations, and product development from research through commercialization.
Retrophin (RTRX) delivered earnings and revenue surprises of -75.00% and -5.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 99 cents. Losses, adjusted for non-recurring costs and stock option expense, came to 63 cents per share. The drug developer posted ...
Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Enrollment ongoing in Phase 3 clinical trials of sparsentan for patients with rare nephropathies.
NEW YORK, NY / ACCESSWIRE / May 7, 2019 / Retrophin, Inc. (NASDAQ: RTRX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 7, 2019 at 4:30 PM Eastern Time. ...
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 13.1% in the 2.5 months of 2019 (including […]
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It might be of some concern to shareholders to see the Retrophin, Inc. (NASDAQ:RTRX) share price down 13% in the last month. In contrast the stock is up over the last three years. In that time, it is up 41%, which isn...
SAN DIEGO, April 23, 2019 -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the.